yingweiwo

SIK

SIK

The AMP-activated protein kinase (AMPK) family includes salt-inducible kinases (SIKs), which are primarily involved in controlling physiological processes that are connected to the energy response, such as gluconeogenesis and lipid metabolism. Three isoforms of the SIK family—SIK1, SIK2, and SIK3—can all function as metabolic transmitters. SIKs have demonstrated self-phosphorylation and are crucial in controlling adrenocortical function in response to high salt or adreno-cortico-tropic hormone (ACTH) stimulation.

The expression of all three SIK family kinases is widespread. Numerous factors, such as high dietary salt intake, ACTH signaling, glucagon signaling, excitable cell depolarization, and circadian rhythms, affect SIK1 mRNA expression. When these kinases are expressed in tissues, however, SIK2 and SIK3 expression is constant. In humans, SIK2 and SIK3 are widely expressed, with the highest levels of SIK2 being found in adipose tissue and the highest levels of SIK3 being found in the brain. Additionally, the dysregulation of these SIK family members in various cancers, such as ovarian, breast, prostate, and lung cancers, suggests that SIKs may play important roles in the development or progression of tumors.

SIK related products

Structure Cat No. Product Name CAS No. Product Description
ARN-3236 V3543 ARN-3236 1613710-01-2 ARN-3236 (ARN3236) is a novel, potent, oral bioavailable and selective inhibitor ofsalt-inducible kinase 2 (SIK2) with anticancer activity.
GLPG3312 V85175 GLPG3312 2340388-72-7
GLPG3970 V74296 GLPG3970 2403733-82-2 GLPG3970 (compound 88) is a first-in-class SIK2/SIK3 inhibitor.
HG-9-91-01 V3380 HG-9-91-01 1456858-58-4 HG-9-91-01 (HG9-91-01) is a novel, potent and highly selective inhibitor of salt-inducible kinase (SIKs) with antidiabetic effects.
MR22 V80835 MR22 3027761-24-3 MR22 is a potent pan-SIK (salt-induced kinase) inhibitor.
Phanginin A V74297 Phanginin A 1011528-58-7 Phanginin A is a potent orally bioactive SIK1 activator.
SIC-19 V86998 SIC-19 713112-69-7 SIC-19 is a SIK2 inhibitor that promotes SIK2 protein degradation through the ubiquitination pathway.
SIK2-IN-1 V76513 SIK2-IN-1 SIK2-IN-1 (compound 8g) is a potent SIK2 inhibitor, more effective than other AMPK kinases.
SIKs-IN-1 V74294 SIKs-IN-1 2927557-06-8 SIKs-IN-1 (compound 8h) is a salt-induced kinase (SIKs) inhibitor and is a pyrimidine-5-carboxamide analogue.
WH-4-025 V74295 WH-4-025 1876463-35-2 WH-4-025 is an inhibitor (blocker/antagonist) of salt-induced kinase (SIK) (WO2016023014 A2).
YKL-06-061 V28380 YKL-06-061 2172617-15-9 YKL-06-061 (YKL06-061) is a novel and potent SIK (salt-inducible kinase) inhibitor (IC50: 6.56 nM/1.77 nM/20.5 nM (SIK1/2/3)) with the potentialto be used as a dermatologic drug impacting UV protection and skin cancer risk.
Contact Us